Adage Capital Partners GP L.L.C. Decreases Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Adage Capital Partners GP L.L.C. decreased its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 66.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,200,000 shares of the company's stock after selling 2,421,899 shares during the quarter. Adage Capital Partners GP L.L.C. owned about 0.11% of Teva Pharmaceutical Industries worth $26,448,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TEVA. MGO One Seven LLC raised its stake in Teva Pharmaceutical Industries by 216.2% during the fourth quarter. MGO One Seven LLC now owns 48,813 shares of the company's stock worth $1,076,000 after buying an additional 33,377 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Teva Pharmaceutical Industries by 148.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,049,388 shares of the company's stock worth $45,170,000 after acquiring an additional 1,223,957 shares during the period. Dark Forest Capital Management LP bought a new position in shares of Teva Pharmaceutical Industries in the 4th quarter worth about $441,000. BlackBarn Capital Partners LP lifted its stake in shares of Teva Pharmaceutical Industries by 107.1% in the 4th quarter. BlackBarn Capital Partners LP now owns 1,050,000 shares of the company's stock valued at $23,142,000 after purchasing an additional 543,029 shares during the period. Finally, Diadema Partners LP bought a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter valued at about $6,677,000. Institutional investors and hedge funds own 54.05% of the company's stock.

Teva Pharmaceutical Industries Stock Up 3.7 %

Shares of TEVA traded up $0.56 on Tuesday, reaching $15.58. The company's stock had a trading volume of 14,075,381 shares, compared to its average volume of 9,953,833. The stock has a market capitalization of $17.67 billion, a PE ratio of -10.74, a PEG ratio of 1.44 and a beta of 0.72. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a twelve month low of $12.47 and a twelve month high of $22.80. The firm has a fifty day moving average of $15.19 and a 200-day moving average of $17.55.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Equities analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on TEVA shares. StockNews.com upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday, April 23rd. Piper Sandler increased their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. UBS Group decreased their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research note on Thursday, January 30th. Barclays cut their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, January 30th. Finally, Bank of America decreased their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research report on Thursday, March 6th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $23.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.